TB Unit, National Infection Service, Public Health England, London, UK
TB Unit, National Infection Service, Public Health England, London, UK.
Eur Respir Rev. 2019 May 29;28(152). doi: 10.1183/16000617.0107-2018. Print 2019 Jun 30.
What is the evidence base for the effectiveness of interventions to reduce tuberculosis (TB) incidence in countries which have low TB incidence?
We conducted a systematic review of interventions for TB control and prevention relevant to low TB incidence settings (<10 cases per 100 000 population). Our analysis was stratified according to "direct" or "indirect" effects on TB incidence. Review quality was assessed using AMSTAR2 criteria. We summarised the strength of review level evidence for interventions as "sufficient", "tentative", "insufficient" or "no" using a framework based on the consistency of evidence within and between reviews.
We found sufficient review level evidence for direct effects on TB incidence/case prevention of vaccination and treatment of latent TB infection. We also found sufficient evidence of beneficial indirect effects attributable to drug susceptibility testing and adverse indirect effects (measured as sub-optimal treatment outcomes) in relation to use of standardised first-line drug regimens for isoniazid-resistant TB and intermittent dosing regimens. We found insufficient review level evidence for direct or indirect effects of interventions in other areas, including screening, adherence, multidrug-resistant TB, and healthcare-associated infection.
Our review has shown a need for stronger evidence to support expert opinion and country experience when formulating TB control policy.
在结核病发病率较低(<10/10 万)的国家,有哪些减少结核病发病率的干预措施的有效性证据?
我们对与低结核病发病率环境相关的结核病控制和预防干预措施进行了系统评价。我们的分析根据对结核病发病率的“直接”或“间接”影响进行分层。使用 AMSTAR2 标准评估了审查质量。我们根据审查内和审查间证据的一致性,使用基于证据强度的框架,将干预措施的审查水平证据总结为“充足”、“暂定”、“不足”或“无”。
我们发现疫苗接种和治疗潜伏性结核感染对结核病发病率/病例预防的直接影响有充足的审查水平证据。我们还发现药物敏感性测试和与使用标准化异烟肼耐药结核病一线药物方案和间歇性给药方案相关的不良间接影响(表现为治疗效果不理想)具有有益的间接影响,这有充足的审查水平证据。我们发现其他领域(包括筛查、依从性、耐多药结核病和医疗保健相关感染)的干预措施的直接或间接影响的审查水平证据不足。
我们的综述表明,在制定结核病控制政策时,需要更多的证据来支持专家意见和国家经验。